Keywords: copaxone, 3rd-qtr, sales, rise, 242m, israel, teva

Copaxone 3rd-qtr sales rise 34% to $242M

Article | 01 November 2004

Israel's Teva Pharmaceutical Industries has revealed that global in-market sales of its multiple sclerosis drug Copaxone (glatiramer) amounted to $242 million ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Teva Pharmaceutical Industries

Go to company listing

Related Drugs

Copaxone

Glatiramer Acetate

Go to drug listing